Eli Lilly eyes Houston for manufacturing plant, seeking tax breaks. The project could create 604 jobs and generate $2.4B in tax revenue over 10 years. Houston Business Journal ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly has proposed investing $5.9 billion to build a pharmaceutical facility in Houston's Generation Park. An application notes Eli Lilly is considering purchasing 236 acres at McCord ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Empower Pharmacy moves to dismiss drugmaker Eli Lilly's false advertising lawsuit expand The exterior of Empower Pharmacy's 85,000-square-foot pharmaceutical compounding facility at 7601 N. Sam ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

Eli Lilly and Company CEO David Ricks stands as President Donald Trump speaks about investing in America in the Cross Hall of the White House, Wednesday, April 30, 2025, in Washington.

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Similarly, Eli Lilly reported, in its FY2024 10K, $13.876 billion in revenue driven by Mounjaro/Zepbound in the U.S. alone, while the total Mounjaro/Zepbound revenue worldwide was $16.466.